NRXP · NRx Pharmaceuticals, Inc.

Summary

NRx Pharmaceuticals, Inc. filed a prospectus supplement on February 17, 2026, for an aggregate of $20,000,000 of common stock issuable under the At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC, dated August 14, 2023, as amended. The filing includes the legal opinion of Cozen O’Connor confirming the validity of the shares.

Key takeaways

• Filed prospectus supplement for $20,000,000 of common stock (par value $0.001 per share)
• Shares issuable under At-The-Market Offering Agreement dated August 14, 2023, amended April 4, 2025
• Sales agent: H.C. Wainwright & Co., LLC
• Registration Statement Form S-3 (File No. 333-288205), effective December 22, 2025
• Legal opinion by Cozen O’Connor filed as Exhibit 5.1
• Consent of Cozen O’Connor as Exhibit 23.1